Serophene

By H. Givess. University of Nebraska, Kearney.

Adverse Efects Excessive administraton may cause hypokalaemia and metabolic alkalosis generic serophene 25 mg with amex, especially in renal impairment; large doses may give rise to sodium accumulaton and oedema seizures; lactc acidosis; pulmonary oedema; hyperventlaton buy serophene with a mastercard. Sodium Chloride Indicatons Electrolyte and fuid replacement; hyponatremia; diabetc ketoacidosis; leg cramps; poisoning purchase serophene 50 mg line. Dose Intravenous infusion Adult and Child- Fluid and electrolyte replacement: determined on the basis of clinical and wherever possible cheap 25 mg serophene amex, electrolyte monitoring. Contraindicatons Hypertension; liver cirrhosis; ischaemic heart disease; nephrotc syndrome; congestve heart failure. Adverse Efects Administraton of large doses may give rise to sodium accumulaton and oedema; vomitng; intraocular coagulopathy. Sodium Lactate Indicatons Perioperatve fuid and electrolyte replacement; hypovolaemic shock; metabolic acidosis; peritoneal dialysis. Dose Intravenous infusion Adult and Child-Fluid and electrolyte replacement or hypovolaemic shock: determined on the basis of clinical and wherever possible, electrolyte monitoring. Contraindicatons Metabolic or respiratory alkalosis; hypocal- caemia or hypochlorhydria; hypernatremia. Precautons Restrict intake in impaired renal functon; cardiac failure, hypertension; peripheral and pulmonary oedema; toxaemia of pregnancy; cortcosteroid therapy; shock; hypoxemia. Adverse Efects Excessive administraton may cause metabolic alkalosis; administraton of large doses may give rise to oedema; tssue necrosis; hypernatremia; hypervolemia; reacton at injecton site. Water for Injecton* Indicatons In preparatons intended for parenteral administraton and in other sterile preparatons. Precautons Preparaton should not be greater than 10%, intravenous preparatons should be administered slowly to prevent haemolysis. Adverse Efects Haemolysis, haemoglobinuria; renal failure; hyperosmolar coma; much frequent and severe rebound efect; hyperglycemia. Vitamins, Minerals and Antanaemic Drugs Vitamins: Vitamins are used for the preventon and treatment of specifc defciency states or when the diet is known to be inadequate. It has ofen been suggested but never convinc- ingly proved, that subclinical vitamin defciencies cause much chronic ill-health and liability to infectons. This has led to enormous consumpton of vitamin preparatons, which have no more than placebo value. Most vitamins are compara- tvely non-toxic but prolonged administraton of high doses of retnol (vitamin A), ergocalciferol (vitamin D2) and pyridoxine (vitamin B6) may have severe adverse efects. Retnol (vitamin A) is a fat-soluble substance stored in body organs, principally the liver. Periodic high-dose supplementa- ton is intended to protect against vitamin A defciency which is associated with ocular defects partcularly xerophthalmia (including night blindness which may progress to severe eye lesions and blindness), and an increased susceptbility to infectons, partcularly measles and diarrhoea. Universal vitamin A distributon involves the periodic administraton of supplemental doses to all preschool-age children with priority given to age groups, 6 months to 3 years, or regions at greatest risk. All mothers in high-risk regions should also receive a high dose of vitamin A within 8 weeks of delivery. Since vitamin A is associated with a teratogenic efect it should be given in smaller doses (no more than 10,000 units/day) to women of child-bearing age. Doses of vitamin A should be admin- istered orally immediately upon diagnosis of xerophthalmia and thereafer patents with acute corneal lesions should be referred to a hospital on an emergency basis. In women of child-bearing age there is a need to balance the possible teratogenic efects of vitamin A should they be pregnant with the serious consequences of xerophthalmia. Where there are severe signs of xerophthalmia high dose treatment as for patents over 1 year should be given. When less severe symp- toms are present (for example night blindness) a much lower dose is recommended. Vitamin A therapy should also be given during epidemics of measles to reduce complicatons. Vitamin B is composed of widely difering substances which are, for convenience, classed as ‘vitamin B complex’. Chronic dry ‘beri-beri’ is characterized by peripheral neurop- athy, muscle wastng and weakness, and paralysis; wet ‘beri- beri’ is characterized by cardiac failure and oedema. Thiamine is given by intravenous injecton in doses of up to 300 mg daily (parenteral preparatons may contain several B group vitamins) as inital treatment in severe defciency states. Ribofavin (vitamin B2) defciency may result from reduced dietary intake or reduced absorpton due to liver disease, alcoholism, chronic infecton or probenecid therapy. Pyridoxine (vitamin B6) defciency is rare as the vitamin is widely distributed in foods, but defciency may occur during isoniazid therapy and is characterized by peripheral neurits. High doses are given in some metabolic disorders, such as hyperoxaluria and it is also used in sideroblastc anaemia. Nicotnic acid inhibits the synthesis of cholesterol and triglyceride and is used in some hyperlipidaemias. Nicotnic acid and nicotnamide are used to prevent and treat nicotnic acid defciency (pellagra). Hydroxocobalamin is the form of vitamin B12 used to treat vitamin B12 defciency due to dietary defciency or malabsorp- ton (see chapter 13. Folic acid should not be used in undiagnosed megaloblastc anaemia unless vitamin B12 is administered concurrently, otherwise neuropathy may be precipitated (see chapter 13. Supplementaton with folic acid 500 µg daily is recommended for women of child-bearing potental in order to reduce the risk of serious neural tube defects in their ofspring. Claims that ascorbic acid is of value in the treatment of common colds are unsubstantated. The term vitamin D covers a range of compounds including ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3). These two compounds are equipotent and either can be used to prevent and treat rickets. Minerals: Calcium gluconate: Calcium supplements are usually only required where dietary calcium intake is defcient. This dietary requirement varies with age and is relatvely greater in child- hood, pregnancy and lactaton due to an increased demand, and in old age, due to impaired absorpton. In osteoporosis, a calcium intake which is double the recommended daily amount reduces the rate of bone loss. In hypocalcaemic tetany calcium gluconate must be given parenterally but plasma calcium must be monitored. The recommended intake of iodine is 150 µg daily (200 µg daily in pregnant and lactaton women); in children the recommended intake of iodine is 50 µg daily for infants under 1 year, 90 µg daily for children aged 2-6 years, and 120 µg daily for children aged 7-12 years. Defciency causes endemic goitre and results in endemic cretnism (characterized by deaf-mutsm, intellectual defcit, spastcity and sometmes hypothyroidism), impaired mental functon in children and adults and an increased inci- dence of stll-births and perinatal and infant mortality. Iodine and iodides may suppress neonatal thyroid functon and in general iodine compounds should be avoided in pregnancy. Where it is essental to prevent neonatal goitre and cretnism, iodine should not be witheld from pregnant women. Control of iodine defciency largely depends upon salt iodizaton with potassium iodide or potassium iodate and through dietary diversifcaton. In areas where iodine defciency disorders are moderate to severe, iodized oil given either before or at any stage of pregnancy is found to be benefcial. Sodium fuoride: Availability of adequate fuoride confers signifcant resistance to dental caries. It is now considered that the topical acton of fuoride on enamel and plaque is more important than the systemic efect. Where the natural fuoride content of the drinking water is signifcantly less than 1 mg per litre, artfcial fuoridaton is the most economical method of supplementng fuoride intake. Daily administra- ton of fuoride tablets or drops is a suitable alternatve, but systemic fuoride supplements should not be prescribed without reference to the fuoride content of the local water supply; they are not advisable when the water contains more than 700 µg per litre. Individuals who are either partcularly caries prone or medically compromized may be given additonal protecton by the use of fuoride rinses or by applicaton of fuoride gels. Rinses may be used daily or weekly; daily use of a less concen- trated rinse is more efectve than weekly use of a more concentrated one. High-strength gels must be applied on a regular basis under professional supervision; extreme cauton is necessary to prevent the child from swallowing any excess. Ascorbic Acid (Vitamin C)* Pregnancy Category-A, C Indicatons Preventon and treatment of scurvy. Adverse Efects Gastrointestnal disturbances reported with large doses; failure of concepton; kidney oxalate stones.

When two or more drugs are concomitantly administered there is always a possibility of pharmacokinetc or pharmacodynamic interacton quality 100mg serophene. The pharmacodynamic interactons can be at the receptor level for competton at same drug target (enzyme/receptor) actng synergistcally or antagonizing the efect of each other purchase generic serophene. The drugs which have narrow therapeutc window have greater potental to cause unexpected adverse efect when their pharmacokinetcs or pharmacodynamics is altered discount serophene 50mg without prescription. The following drug categories are considered as drugs of narrow therapeutc window: Antepileptcs order line serophene, antcoagulants, antcancers, xanthenes, antde- pressants, antarrhythmics etc. Lovastatn Avoid concomitant use Sildenafl Dose reducton of sildenafl may be required. Simvastatn Avoid concomitant use Sirolimus Elevaton in serum sirolimus level Tacrolimus Elevaton in serum sirolimus level Tadalafl Dose reducton of tadalafl may be required. Tetracycline Reduced absorpton of oral tetracycline Quinolone antbiotcs Reduced absorpton of quinolone antbiotcs Almunium and Magnesium Decreased absorpton of Hydroxides strontum ranelate. Allopurinol Reduced side efects; reduced clearance of actve metabolite with protein-poor diet Amiodarone Enhances both the rate and extent of absorpton. Potassium salts Reduced side efects Prednisolone Reduced side efects Prednisone Reduced stomach irritaton Procainamide Reduced side efects; increased absorpton with fat Propranolol Slows rate but increases extent of absorpton Quinine Reduced side efects Ritonavir Increased absorpton Salsalate Reduced stomach irritaton. Intake caulifower, of such foods should be legumes, limited, and the amount mayonnaise, consumed daily should soybean oils and remain constant. However there has to be moderate to severe hepatc impair- ment to signifcantly alter the response to drugs as liver has a large reserve capacity. Hepatc impairment may alter response to drugs not only because of its role in metabolism of drugs but it also afects their absorpton and distributon. Looking at the importance of liver in dealing with the drug, knowledge of a patent’s hepatc functon is required for the safe prescribing of many drugs. Unlike renal disease, where estmaton of renal functon based on creatnine clearance can fairly help in knowing the drug eliminaton and hence dose adjustment, there is no endogenous marker for hepatc clearance that can be used as a guide for drug dosing. Hepatc impairment can lead to altered response to drugs due to all or some of the following reasons: • Metabolism of many drugs depend on adequate liver functon. Generally, metabolism result in the loss of pharmacological actvity and therefore reduced metabolism in case of impaired liver functon can lead to the accumulaton of drug in the body to the toxic level at the normal dose. However in some cases drugs are metabolised to the actve form and in these drugs normal dose may not be able to achieve desired response. If such drug is to be administered orally to cirrhotc patents, their inital dose has to be reduced according to their hepatc extracton. For drugs with low bioavailability (low hepatc extracton), hepatc clearance may be afected due to impaired metabolism. For such drugs only the maintenance dose has to be adjusted according to est- mated decrease in their hepatc metabolism. Impaired gastrointestnal motlity seen in cirrhotc patents can lead to delayed drug absorpton • Volume of distributon of hydrophilic drugs is increased due to presence of oedema and/or ascits. Hence, loading dose of these drugs may have to be increased if a rapid acton is required. On the other hand increase in volume of distributon is associated with an increase in the eliminaton half life of such drugs. The use of certain drugs in patents with cirrhosis may increase the risk of hepatc decompensaton. In patents with impaired liver functon dose related hepatotoxic reacton may occur at lower doses. Drugs that cause fuid retenton (for example, prednisolone, ibuprofen, dexamethasone etc. Sensitvity of brain to depressant acton of some drugs( for example, morphine and barbiturates) is markedly increased in cirrhotc patents and can precipitate hepatc encephalopathy at normal doses. As evident from above, there is a complex interactons between the drugs and liver functon. Absence of any endog- enous marker for hepatc clearance makes it highly difcult to accurately adjust the dose of various drugs in hepatc impairment. Therefore, if no immediate pharmacological efect is needed, drug therapy should be started cautously in these patents and ttrated individually untl desired efect is achieved or toxicity appears. If such drugs are administered orally, both loading dose and maintenance doses have to be reduced by ≥ 50% of the normal dose, depending on the severity of hepatc impairment. The table provided is not exhaustve and abscence from this table does not imply safety of drug, it is therefore important to refer to the indi- vidual drug entries. Antacids containing high amount of sodium to be avoided in patents with fuid retenton. Amidotrizoate Use with cauton Amitryptyline Avoid in severe Increased sedaton hepatc impairment Amlodipine Reduce dose Half life of a mlodipine is prolonged Amodiaquine Avoid in hepatc impairment Amoxycillin + Use with cauton Monitor liver functon, Clavulanic acid cholestatc jaundice reported either during or shortly afer therapy (more common in males and patents over 65 years), duraton of treatment should not exceed 2 weeks. Cyclophosphamide Reduce dose Monitor plasma level Cyclosporine Reduce dose and Hepatotoxic use with cauton Cytarabine Reduce dose Dacarbazine Avoid in severe Dose reducton in mild hepatc impairment to moderate hepatc impairment. Daunorubicin Reduce dose Use with cauton as toxicity increases in hepatc impairment. Enalapril Use with cauton Closely monitor liver functon in patents with hepatc impairment Ergometrine Avoid in severe hepatc impairment Erythromycin Avoid in severe May cause idiosyncratc hepatc impairment hepatotoxicity Ethinylestradiol Avoid See also Contraceptves, Oral Etoposide Avoid in severe Increased risk of toxicity hepatc impairment in case of hepatc impairment Fluconazole Use with cauton Hepatotoxicity 5-Fluorouracil Use with cauton; dose reducton may be required Fluoxetne Reduce dose or administer on alternate days Fluphenazine Avoid in severe Hepatotoxic, can hepatc impairment precipitate coma Furosemide Avoid or use Hypokalaemia may with cauton in precipitate coma (use severe hepatc potassium sparing diuretc impairment to prevent this); Increased risk of hypomagnesaemia in alcoholic cirrhosis Glibenclamide Avoid or reduce Increased risk of the dose hypoglycaemia. Levonorgestrel Use with cauton in actve liver disease and recurrent cholestatc jaundice Lidocaine Avoid or reduce the dose in severe hepatc impairment Magnesium Avoid in hepatc hydroxide/sulphate coma if risk of renal failure Medroxyproges- Avoid in actve liver Avoid if history of pruritus terone disease. Nitrofurantoin Use with cauton Cholestatc jaundice and chronic actve hepatts reported Norethisterone Avoid in actve liver Avoid if history of pruritus disease. Cauton in moderate hepatc impairment Simvastatn Avoid in actve liver disease or unexplained persistent elevaton in serum transaminases Sodium Avoid in severe nitroprusside hepatc impairment Sulfadiazine Avoid in severe hepatc impairment Sulfamethoxazole + Avoid in severe trimethoprim hepatc impairment Suxamethonium Prolonged apnoea may occur in severe liver disease due to reduced hepatc synthesis of plasma cholinesterase Testosterone Preferably avoid Possibility of dose related toxicity and fuid retenton. Toxicity to the infant can occur if the drug enters the milk in pharmacologically signifcant quanttes. The concentraton in milk of some drugs (for example, iodides) may exceed that in the maternal plasma so that therapeutc doses in the mother may cause toxicity to the infant. Drugs in breast milk may, at least theoretcally, cause hypersensitvity in the infant even when the concentraton is too low for a pharma- cological efect. The following table lists drugs: • which should be used with cauton or which are contrain- dicated in lactaton for the reasons given above; • which are not known to be harmful to the infant although they are present in milk in signifcant amounts. For many drugs insufcient evidence is available to provide guidance and it is advisable to administer only drugs essental to a mother during lactaton. Because of the inadequacy of informaton on drugs in breast milk the following table should be used only as a guide; absence from the table does not imply safety. It is important to remember this when prescribing for a woman of childbearing age. This includes untreated illness, impaired maternal compliance, suboptmal treatment and treatment failures. Major congenital malformatons occur in 2–4% of all live births, 15% of all diagnosed pregnancies will result in fetal loss. During the frst trimester drugs may produce congenital malformatons (teratogenesis), and the greater risk is from third to the eleventh week of pregnancy. During the second and third trimester, drugs may afect the growth and functonal development of the fetus or have toxic efects on fetal tssues. Drugs given shortly before term or during labor may have adverse efects on labor or on the neonate afer delivery. Few drugs have been shown conclusively to be teratogenic in man but no drug is safe beyond all doubt in early pregnancy. Screening procedures are available where there is a known risk of certain defects. Prescribing in Pregnancy Since, approximately 50% of pregnancies are unplanned and rest 50% are planned, if possible, counseling of women before a planned pregnancy should be carried out including discussion of risks associated with specifc therapeutc agents, traditonal drugs (alternatve medicines), over the counter drugs and substances of abuse such as opioids, smoking, alcohol etc. Drugs should be prescribed in pregnancy only if the expected benefts to the mother are thought to be greater than the risk to the fetus. Drugs which have been used extensively in pregnancy and appear to be usually safe should be prescribed in preference to new or untried drugs and the smallest efectve dose should be used. Keeping in view the prevalence of irratonal polypharmacy, emphasis should be laid on promotng the use of well known single component drugs to multcomponent drugs. Since, there does appear to be an associaton of very potent topical cortcosteroids with low birth weight, even the dermatological drug products being used should be cautously selected and used. The pronounced and progressive change in drug dispositon that occurs during pregnancy is another major reason which calls for atenton. Major physiological changes which infuence drug dispositon in mother and fetus are: S.

A schematic representation of the strategy used to explore the structure–activity relationships carried out is illustrated in Figure 11 buy 100 mg serophene visa. Alkyl amides were found to be active cheap serophene 25mg overnight delivery, particularly when located at the 6- and 7-positions of the benzoxazole core order serophene 25mg on line, and with a clear size dependence purchase serophene once a day, although they were also found to suffer from poor metabolic stability, a problem that was further apparent following in vivo dosing. Other linking groups were investigated, including thioamides, amines and sulfonamides, and all were less active than the starting compound. In particular, this structural change appeared to confer preferable pharmacokinetic properties on the compounds, as well as having improved solubility over its amide analogue. For Region B, the benzoxazole, a range of alternative cores were explored, including the isosteric replacements benzothiazole and benzimidazole, as well as a benzofuran analogue. Of these, only the benzothiazole exhibited any appreciable activity, being approximately equipotent with the benzoxazole, but otherwise there was seen as being no advantage to a core switch, so focus was maintained on the benzoxazole. A wide range of mono and bicyclic cycloalkyl, aryl and heteroaryl rings were examined as a replacement for the phenyl ring in Region C of the molecule. Simple acyclic alkyl derivatives were found to be inactive, as were compounds Figure 11. View Online Drug Discovery Approaches for Rare Neuromuscular Diseases 291 bearing 2-aryl substituents with an ortho substituent. Preferable substituents on the 2-aryl ring were found to be those that were relatively lipophilic, and positioned at the 4- or 3,4-positions, with particularly favoured groups being 3,4-dichloro and 2-naphthyl. Compound plasma concentrations stabilised aer an initial drop, and the level being seen was felt by the authors to be above that which was antici- pated to provide therapeutic benet for at least 60% of the time. Et, iPr) exhibited moderate levels of activity in the H2K luciferase reporter assay View Online 292 Chapter 11 Figure 11. Modication of the benzotriazole to the less polar indazole was also investigated, with the authors synthesising a number of key compounds which crossed over with the corresponding benzotriazoles. Similar structure– activity trends to those seen in the corresponding benzoxazole series were observed, with only the amide derivative showing any appreciable activity (11. Both were found to have low to moderate kinetic solubility, but more encouragingly they had low meta- bolic turnover upon incubation with human liver microsomes. The authors conclude by stating that these data were encouraging enough to progress the compounds for further evaluation, although no in vivo data, such as pharmacokinetic proling and/or efficacy testing, has been reported for either to date. Khurana and co- workers have also recently described their efforts to identify upregulators of utrophin production, using a screen of small molecules in an assay designed to assess the ability to activate the utrophin A promoter in C2C12utrn cells (C2C12 cells which have been stably transfected with the utrophin A promoter linked to a luciferase reporter). Of these, approximately 90% were drugs which were approved for use in humans, with the remainder being natural products. Importantly then, the vast majority of these compounds will have entered clinical trials at some stage. Details on dosing, efficacy, alternative potential modes of action and most importantly (given the paediatric, chronic nature of the disease) toxicology proles should also be accessible. View Online Drug Discovery Approaches for Rare Neuromuscular Diseases 293 Figure 11. Dose–response assays on all 14 conrmed hit compounds generated data showing dose-dependent responses for most, but for several examples cyto- toxicity was observed at higher screening concentrations, as adjudged by a drop in luciferase response. Further, they note that follow-up experiments of a similar nature to those previously described for nabumetone are under way for several of the other non-cytotoxic hit compounds, although there is no mention of in vivo testing of any of the compounds in the mdx mouse model. The authors acknowledge that there are other utrophin promoters, acti- vation of which could also increase levels of the protein, as well as post- translational strategies. In an effort to address the latter deciency in more recent work, they have described a new cell-based assay designed to identify compounds which upregulate utrophin levels through post-translational mechanisms, although no reports of compound libraries being screened using it have appeared yet. Compound struc- tures, and detailed information about activity levels and any follow-up conr- matory tests, have not yet been published. Whether this is directly connected with other work on utrophin modulation by the same organisation is unclear. The calpain enzymes are a family of cysteine proteases consisting of around 15 members, and which have been estab- lished as having diverse physiological functions including signal View Online 294 Chapter 11 View Online Drug Discovery Approaches for Rare Neuromuscular Diseases 295 transduction, proliferation, differentiation and apoptosis. They are calcium- dependent enzymes, with various isoforms being ubiquitously expressed, and others being more specically localised in tissues including skeletal muscle (calpain 3) and the testis (calpains 5, 11 and 13). View Online 296 Chapter 11 functional groups as well as the lipoic acid derivative, all of which are intended to act as muscle-targeting motifs. However, when studies were undertaken using a transgenic mouse overexpressing the endogenous calpain inhibitor calpastatin, crossed with the mdx mouse, no histopathological improvement was seen. While it is clearly important that further detailed studies are undertaken, the suggestion from these results is that the observed benet gained from treatment with these bifunctional molecules was seen solely due to inhibition of the proteasome activity. Furthermore, the data also suggest a potentially productive line of research would be a detailed evaluation of monofunctional proteasome inhibitors, because these represent a class of drugs including bortezomib 11. Although the target indication of interest to the project team was neurodegenerative disease, given the ther- apeutic possibilities associated with modulation of both functional motifs, wider application of these compounds could be reasonably anticipated. As well as the structure–activity relationships described in the original medicinal chemistry papers, the compound series advanced further, with examples also having undergone in vivo testing. As with the previously described ketoamide dual inhibitors,153 it is not clear to what extent any improvement seen is attrib- utable to calpain inhibition alone. Three subtypes of receptor have been described: a, b/g and d, with View Online Drug Discovery Approaches for Rare Neuromuscular Diseases 297 Figure 11. Histone deacetylase inhibitors fall into the class of agents known as epigenetic modulators. Although the precise mech- anisms in play are not clear, inhibitor treatment was shown to increase levels of the myostatin antagonist follistatin in muscle satellite cells, which was suggested to contribute to the functional improvements. What was particularly encour- aging was that this activity translated into efficacy in the mdx mouse Figure 11. Of note in this latter section of the experiment was that the mdx mice used were 10 weeks old when dosing was initiated. This is unusual in experiments intended to assess the effect of new drugs on the mdx phenotype, because by that stage there has already been a considerable amount of muscle degen- eration and regeneration taking place; dosing from around the 3 week postnatal period is more usual. Furthermore, although the compounds were dosed orally, this was not undertaken using oral gavage, but by mixing compound with the food. Although there appeared to be a reasonably consistent amount of food intake between the various animals, gavage dosing might be expected to give more consistent dosing results. The authors speculated that the mechanism of action could involve calcium trafficking. Altering pH and hence transmembrane potential in turn + 2+ inuences specic ion channel activities, particularly Na and Ca. Although there are clear limitations to the screening platform, such as clarity/consistency on compound dose levels, the value of using an in vivo disease model with a dystrophin-like gene is clear. For any future screening programme, as well as identifying new lead molecules it would be important to establish the proles of previously described compounds which work through the full range of mechanisms described herein. In this manner it would be possible to assess the scope and limitations of the assay system, particularly for evaluating compound modes of action which are indepen- dent of dystrophin. A dual approach, combining myostatin knockdown with myostatin inhi- bition, has been investigated by several groups, and shown to be bene- cial. The therapeutic potential of the protein was further illustrated in studies using biglycan null mice, which were shown to exhibit reduced levels of utrophin expression, along with reduced muscle function. Histological improvement in muscle structure and functional benet were also seen. Furthermore, efficacy has yet to be demonstrated using in vivo systems other than the mdx mouse. An important advantage of the approach relative to gene therapy is that the protein can be delivered systemically using intra- peritoneal injection. Fallon also demonstrated that the agent is well tolerated following chronic dosing and appears to be physiologically stable for suffi- cient time to provide sustained functional benet. It is under development by Tirvorsan, a spin-out company from Brown University co-founded by Fallon. Using this assay the Prestwick Chemical Library (1120 compounds) was screened, and seven compounds found to give a bire- fringement readout equivalent to wild-type, although further analysis using an antibody to dystrophin established that this effect was not due to resto- ration of dystrophin production. These results conrm the published work on sildenal in the mdx mouse (see Section 11. It is known to have in excess of 40 protein binding partners, and is found at varying levels in most tissues, with particularly high concentrations being localised in the brain and spinal cord.